glp 1 drugs medicaid More state programs may soon cover Wegovy, Zepbound Medicaid Coverage of and Spending

The propensity score was estimated using logistic regression as the probability of starting a GLP1 receptor agonist versus a DPP4 inhibitor conditional on a number of variables, including sociodemographic characteristics, medical history, other diabetes treatment, and markers of healthcare use, at cohort entry and stratified by country (etable 3)

Nehmen Sie nicht zwei Dosen gleichzeitig ein

What's Next in the Triple Agonist Research Pipeline Beyond retatrutide, other triple agonist candidates are in earlier-stage clinical development

Phase III results for retatrutide are set to be released later in 2025 and in early 2026, but an earlier phase II trial recorded between a 7.2% and 17.5% reduction in body weight after 24 weeks, depending on the dose (7.2% on 1mg, 17.5% on 12mg), and up to a 24.2% reduction in body weight after 48 weeks for those on 12mg (-8.7% change for those on 1mg) 8

Glucagon-like peptide-1 receptor agonists and pancreatitis meta-analysis